Candonilimab Combined With Fruquintinib and Paclitaxel Albumin-Bound as Second-Line Treatment for Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma

This is a Phase II Study of Candonilimab Combined with Fruquintinib and Paclitaxel Albumin-Bound as Second-Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Trial Details

NCT ID
NCT07920224
Phase
PHASE2
Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Status
RECRUITING
Cancer Type
Adenocarcinoma Esophageal Cancer
Interventions
  • candonilimab combined with fruquintinib and paclitaxel albumin-bound
Locations (sample)
  • Wuhan, Hubei, China|30.58333,114.26667

Key Eligibility Criteria

  • Have a full understanding of the study and voluntarily sign the informed consent form;
  • Aged 18 to 75 years (inclusive);
  • Pathologically confirmed advanced gastric or gastroesophageal junction adenocarcinoma;
  • Prior failure of first-line standard chemotherapy;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Esophageal Cancer Trials on Trialify →